ADVANCED NT has a total of 16 patent applications. It decreased the IP activity by 87.0%. Its first patent ever was published in 2015. It filed its patents most often in Republic of Korea, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, measurement and foods and drinks are GUT GUIDE OY, WUZHOU PRODUCTS QUALITY INSPECTION INST and UNIV ROUEN CENTRE HOSPITALIER.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 6 | |
#2 | United States | 4 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | China | 1 | |
#5 | EPO (European Patent Office) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Foods and drinks | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials | |
#4 | Measuring microorganism processes | |
#5 | Foods | |
#6 | Special foods |
# | Name | Total Patents |
---|---|---|
#1 | Lee Sang Kun | 16 |
#2 | Chu Kon | 16 |
#3 | Kim Man Ho | 13 |
#4 | Jung Keun Hwa | 13 |
#5 | Lee Soon Tae | 13 |
#6 | Moon Jang Sup | 6 |
#7 | Jeon Dae Jong | 5 |
#8 | Jung Keun-Hwa | 3 |
#9 | Jeon Daejong | 3 |
#10 | Kim Manho | 3 |
Publication | Filing date | Title |
---|---|---|
KR20190098677A | Dosage escalation regimen of lamotrigine for the prevention of adverse drug reaction | |
KR20190057145A | Identification of type of autoimmune encephalitis using HLA genotype test | |
KR101739703B1 | The method of diagnosing encephalitis and the apparatus thereof based on TRAIL measurement | |
KR101707373B1 | The mixture of D-serine and Caffeine for prevention of weaken of learning ability by stress, suppression of weaken of memory power by stress or enhancement of learning ability or memory power and the functional food composition including it | |
KR20170072580A | The detection method of miRNA-206, the method of providing information for diagnosis and prognostic analysis of mood disorders, the composition targeting miRNA-206 | |
KR20170052400A | The pharmaceutical composition for the prophylaxis or treatment of epilepsy or seizure-related disease targeting miRNA to regulate the expression of TSC1 and mTOR protein and method for screening |